Idt Australia Limited · ASX:IDT
Idt Australia — Q3 FY24 Earnings Presentation
16 slides from Idt Australia's earnings presentation, May 2024
Slide 1: FY24 Market Update
FY24 Market Update ae ~ A | Gd
Slide 2: Disclaimer and Important Notices
Disclaimer and Important Notices This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It contains general background information only which is current at the date of this presentation unless otherwise specified. It contains selected summary information and does not
Slide 3: IDT Overview
IDT Overview Innovative Drug Design & Manufacturing 50 Years of Operational Excellence with 30 Novel Chemical Entities Leveraged to new and Clear Path to Return to Profitability fast growing Markets ▪ Revenue in first three quarters of FY24 ▪ Unique capabilities in mRNA and has already exceeded all
Slide 4: Core Pillars
Core Pillars High Growth Opportunities Active Pharmaceutical Ingredients Specialty Orals Advanced Therapies • IDT’s original business • Tablet, capsules and liquid orals • High value platforms in emerging markets • Reimagining this strategic pillar to focus on • Emerging markets in mental health, of
Slide 5: IDT in the Press
IDT in the Press IDT Australia FY24 Market Update
Slide 6: Victorian Government Grant
Victorian Government Grant Australia’s 1st Commercial ADC Facility Victorian Government will partially fund The $3.8M cGMP facility targets the design, fit out, equip of the US$140B global ADC market* ADC facility Australia will have ability to make cutting- ADCs are smart drugs that target cancer e
Slide 7: IDT Secures Contract with Sanofi Australia
IDT Secures Contract with Sanofi Australia Manufacture mRNA pipeline • Sanofi and IDT complete a Master Service Agreement to support the cGMP manufacture of Sanofi’s global mRNA assets under development • The contract entails collaboration between IDT and Sanofi to advance mRNA- based vaccine formul
Slide 8: Largest Addressable Markets: Advanced Therapies
Largest Addressable Markets Advanced Therapies | Leveraged to Multiple Lucrative Opportunities ASEPTIC FILL & FINISH(ADC & mRNA) $13.1B $3.4B $805M T A M S A M S O M Global market forecast to hit Forecast to reach ~US$3.4B by 2026, Estimated using on site capacity and future US$13.1B by 2026 represe
Slide 9: Largest Addressable Markets: Specialty Orals
Largest Addressable Markets Specialty Orals | Leveraged to Multiple Lucrative Opportunities MEDICINAL CANNABIS & PSYCHEDELICS $64B $57B $72M T A M S A M S O M Global market forecast to hit Forecast to reach ~US$57B by 2026, Estimated using current on site capacity at US$64B by 2026 representing part
Slide 10: Largest Addressable Markets: API Manufacturing
Largest Addressable Markets API Manufacturing | Leveraged to Multiple Lucrative Opportunities API PRODUCTION $250B $199B $18M T A M S A M S O M Global market forecast to hit Forecast to reach ~US$199B by 2026, Estimated using current site capacity only, US$250B by 2026 representing part of the TAM t
Slide 11: Q3 FY24 Revenue
Q3 FY24 Revenue Q3 FY24 Revenue by Business Pillars* +48% Significant Jump over Q3 FY23 REVENUE $3.5 $3.2M Millions $3.0 $2.5 $2.1M REVENUE GROWTH Continued strong growth Strong sales pipeline $2.0 across all pillars pushes Q3 and increasing global FY24 unaudited revenue demand for CDMO up 48% pcp a
Slide 12: Key Metrics FY23 v FY24 (Q1-Q3)
Key Metrics FY23 v FY24 (Q1-Q3) YTD Q3 FY23 FY24 (Q1-Q3) (Q1-Q3) Revenue $3.9M $8.9M Facility Utilisation <5% Peak 35% Facility Recommission 1 3 Direct Staff 15% 49% Capex $0.5M $1.0M Pipeline $12M $26M Notes: Facility utilisation means full weekly operation of all available facilities at IDT Facili
Slide 13: Achievements Over The Past Year
Achievements Over The Past Year Well Placed to Grow In FY25 and Beyond S U S T A I N A B L E Completed G R O W T H Work-in-progress K I C K S T A R T Become a Manufacturing Hub of P R O F I T A B I L I T Y Excellence for mRNA and ADCs v Build a diverse client portfolio while U N L O C K N E
Slide 14: FY24 Revenue Guidance
FY24 FY24 Revenue Expected to Jump 84%-91% YoY* $26.6M Revenue (+17% pcp) $25 Millions Guidance* $20 $15 Disbursements/ Other Income $13.4M Advanced Therapies $12.9M 4QFY24 +$4M to Forecast Step Change $10 $8.9M $4.5M Revenue* Speciality Orals $7M Q4 FY24 revenue expected to API Manufacturing jump b
Slide 15: Growth Outlook
Growth Outlook Drivers in FY25 and Beyond R E V E N U E R A M P - U P C A S H F L O W M I L E S T O N E Forecast FY24 unaudited revenue of $12.9M to $13.4M On track to deliver first quarter of positive (vs. FY23: $7M) Sales pipeline of $26M# underpins operating cash flow before end of CY24 continued
Slide 16: Our Glossary
Our A D C Antibody Drug Conjugate M D M A Methylene-dioxy-meth-amphetamine Glossary A P I Active Pharmaceutical Ingredient O D C Office of Drug Control A S P Aseptic Sterile Processing P T S D Post Traumatic Stress Disorder Acronym C D M O Contract Development Manufacturing S A S Special Access Sche